Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
| Autor: | Anton De Spiegeleer, Myriam Alexander, David S. Fedson, Jens T. Van Praet, Bart De Spiegeleer, Geert Byttebier, Bo E. H. Saxberg, Karolien Vanhove, Luc Belmans, Reinhilde Reybrouck, Nick Devrecker, Evelien Wynendaele |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak ACE inhibitors Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunometabolism 030231 tropical medicine Immunology Host response Angiotensin-Converting Enzyme Inhibitors Hospital mortality statins Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Belgium Internal medicine Pandemic medicine Humans Immunology and Allergy cardiovascular diseases Hospital Mortality 030212 general & internal medicine Endothelial dysfunction Available drugs Pandemics propensity score Pharmacology SARS-CoV-2 business.industry COVID-19 medicine.disease mortality Clinical trial angiotensin receptor blockers Hypertension Observational study Angiotensin Receptor Blockers Hydroxymethylglutaryl-CoA Reductase Inhibitors business case-control Research Article Research Paper |
| Zdroj: | Human Vaccines & Immunotherapeutics article-version (VoR) Version of Record |
| ISSN: | 2164-554X 2164-5515 |
| Popis: | The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR=0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|